Axmed
Axmed is a Basel-headquartered B2B digital marketplace that aggregates demand from governments, NGOs, and healthcare procurers in low- and middle-income countries to procure essential medicines directly from vetted global pharmaceutical suppliers at lower cost.
- Company typePrivate
- Founded2024
- HeadquartersBasel, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What Axmed does
Axmed is a Basel, Switzerland-headquartered B2B digital marketplace that connects healthcare procurers in low- and middle-income countries (LMICs) with vetted global and regional pharmaceutical suppliers. Founded in 2024 with a regional hub in Nairobi, Kenya, the company targets governments, NGOs, and mission-driven private procurers in Sub-Saharan Africa and other emerging markets, addressing fragmented LMIC demand where traditional procurement markups of around 250% are commonplace. Its integrated platform combines a marketplace that aggregates demand and enables direct manufacturer contracting, a Logistics SaaS layer that coordinates with top global logistics partners, a Global Health Advisory service for procurement strategy, and embedded financing through the Revolving Inventory Financing Facility (RIFF) and a $5 million Gates Foundation-backed Matching Fund for maternal, newborn, and child health (MNCH) procurement. Axmed caps marketplace markup at 10% and reports redeploying 30% of profits back into the health systems it serves, while claiming average cost savings of around 35% for customers.
The business operates a transaction-fee model capped at 10%, supplemented by managed-services revenue from logistics coordination and financing arrangements, with go-to-market executed through enterprise field sales to governments and institutional buyers alongside partnership-driven introductions via NGOs and donor ecosystems. Named customers and partners include the Government of Burkina Faso ($7M REACH programme agreement for up to 16 million doses of azithromycin), LifeNet International, Every Pregnancy, MEDS Kenya, CHAN Nigeria, and Emcure Pharmaceuticals. By year-end 2025, Axmed reported reaching 4.2 million patients (up from ~750,000 in 2024), delivering over 1,800 metric tonnes of healthcare products across 5,000+ SKUs in 10+ therapeutic areas, with 130+ commercially active procurers and suppliers and 12x year-on-year revenue growth.
The company has raised approximately $13 million in total capital, comprising a $2 million seed round led by Founderful Ventures and roughly $11 million in non-dilutive grants from the Bill & Melinda Gates Foundation, and has publicly targeted operating in 20+ countries by end of 2026 and reaching 50 million patients within three years and 100 million within five years. Management includes co-founders Emmanuel Akpakwu (CEO), Felix Ohnmacht (CCO), Sofía Radley Searle (COO), and Mattia Albergante (CTO).
Axmed firmographics
Firmographics- Name
- Axmed
- Legal name
- Axmed
- Website
- https://axmedrx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Axmed is a Basel-headquartered B2B digital marketplace that aggregates demand from governments, NGOs, and healthcare procurers in low- and middle-income countries to procure essential medicines directly from vetted global pharmaceutical suppliers at lower cost.
- Ownership category
- akta.pro rank
Axmed industry classification
Industry- Product category
- Healthcare Procurement Marketplace
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Wholesale Trade Agents and Brokers (42512)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- B2B Marketplaces & Wholesale Platforms (BPAMAGAD)
- akta.pro secondary industries
- Pricing & Contracting Strategy (HLAIAKAA), Channel & Trade Strategy (Gross-to-Net, Distribution Economics) (HLAIAKAI)
Keywords
Where Axmed is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Axmed business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Marketplace Transaction Fees: Axmed operates a B2B marketplace that connects healthcare procurers with suppliers. The company caps its markup at 10% and redeploys 30% of its profits back into health systems it serves, indicating a transaction-based revenue model with a social-impact pricing structure.
- Logistics and Financing Services: Integrated financing solutions and logistics support are embedded in the platform, with the Revolving Inventory Financing Facility (RIFF) providing capital access to procurers. Revenue is derived from financing arrangements and logistics coordination services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Platform access and marketplace |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Axmed product offering
Product offeringCore offering
Axmed operates a B2B digital marketplace that aggregates fragmented demand from healthcare procurers across low- and middle-income countries and connects them directly with vetted pharmaceutical manufacturers and suppliers. The platform integrates demand aggregation, price transparency, logistics coordination, and trade financing (RIFF and a $5M Matching Fund) to reduce medicine procurement costs by over 35% for governments, NGOs, and mission-driven private procurers in LMICs.
Product overview
Axmed operates a unified B2B technology platform for medicine procurement in low- and middle-income countries, comprising three core products: the Axmed Marketplace (B2B marketplace connecting procurers with suppliers), Logistics SaaS (end-to-end logistics support), and Global Health Advisory (GHA) services. The platform is complemented by two integrated financing solutions: the Revolving Inventory Financing Facility (RIFF) for affordable capital access and the $5M Axmed Matching Fund for MNCH procurement, all designed to work together to reduce costs by over 35% while expanding access to essential medicines across Africa and emerging markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Axmed Marketplace A global B2B marketplace connecting healthcare procurers in low- and middle-income countries with vetted pharmaceutical suppliers. The platform aggregates fragmented demand to negotiate directly with manufacturers, reducing procurement costs by over 35% and providing access to 5,000+ products across 10+ therapeutic areas.
- Logistics SaaS Integrated end-to-end logistics solution connecting buyers with top global logistics partners to streamline delivery of medicines and healthcare products across LMICs.
- Global Health Advisory (GHA) Advisory service supporting governments and institutional procurers with procurement strategy, health system strengthening, and access to capital for essential medicines procurement.
- Revolving Inventory Financing Facility (RIFF) An integrated supply capital facility and trade financing solution that bridges access to finance with access to quality medicines, empowering third-sector procurers to stock life-saving products in emerging markets.
Quantifiable outcome
- 4.2 million patients reached in 2025, up from 750,000 in 2024
- +5 more outcomes
Companies that use Axmed
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Axmed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Axmed partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Government of Burkina Faso (REACH Programme)core$7 million long-term supply agreement under the Resiliency through Azithromycin for Children (REACH) programme to deliver up to 16 million doses of quality-assured azithromycin to children under five in Burkina Faso over three years, supporting reduction of preventable child mortality from bacterial infections. The agreement operates through Burkina Faso's national health ecosystem.
- LifeNet InternationalcoreTransformative partnership to expand access to essential maternal and newborn health products in Africa. LifeNet provides healthcare capacity building and training, while Axmed provides its procurement platform for medical supplies. The collaboration has already contributed to zero maternal deaths at a clinic in Northern Ghana and spans across underserved regions.
- Every PregnancycorePartnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis. Every Pregnancy partners gain access to affordable and quality medicines through Axmed's B2B marketplace, rooted in a shared mission to ensure safe pregnancies and healthy babies.
- Emcure PharmaceuticalscoreUnite to combat maternal and newborn mortality and promote equitable healthcare access. The collaboration combines Emcure's pharmaceutical portfolio with Axmed's procurement platform to transform global health outcomes.
- MEDS Kenya (Mission for Essential Drugs and Supplies)coreAxmed partners with MEDS Kenya to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.
- CHAN Nigeria (Christian Health Association of Nigeria)coreAxmed partners with CHAN Nigeria to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Axmed competitors and assessment
Company assessmentDirect peers
- mPharma: Ghana-based health tech company operating a pharmaceutical supply chain and inventory-financing platform across Africa. Directly comparable to Axmed in serving African healthcare buyers with consolidated pharmaceutical procurement and financing.
- Field Intelligence: Kenya-based pharmaceutical inventory-management and distribution-as-a-service platform serving African pharmacies and clinics. Highly comparable B2B pharma distribution model with embedded financing, mirroring Axmed's RIFF-driven approach.
- DrugStoc: Nigeria-based B2B pharmaceutical e-commerce and distribution platform connecting pharmacies and hospitals with verified manufacturers. Direct marketplace competitor to Axmed in West Africa.
- RxAll: Nigeria/US-based digital pharmaceutical marketplace and quality-verification platform serving African buyers. Comparable two-sided B2B pharma marketplace targeting LMIC procurement.
- Shelf Life: Kenya-based inventory-financing and pharmaceutical distribution platform for African pharmacies. Closely mirrors Axmed's combination of B2B procurement with embedded working capital.
- Sproxil: Nigeria-based anti-counterfeit and supply chain authentication platform for pharmaceuticals in emerging markets. Comparable in addressing trust and quality-assurance gaps in African pharmaceutical supply chains.
- PharmaSecure: India/US-based pharmaceutical supply chain verification and patient-engagement platform serving emerging markets. Adjacent but comparable in enabling pharmaceutical supply integrity in LMICs.
Emerging players
- Zipline: US/Rwanda-based autonomous medical delivery service operating in several African countries. Comparable in building healthcare logistics infrastructure for LMICs, though focused on last-mile delivery rather than B2B procurement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Axmed social profiles
Digital presenceAxmed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axmed leadership team
Management profileNumber of profiles
Profiles4 records
Axmed funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axmed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axmed
What does Axmed do?
Axmed operates a B2B digital marketplace that aggregates fragmented demand from healthcare procurers across low- and middle-income countries and connects them directly with vetted pharmaceutical manufacturers and suppliers. The platform integrates demand aggregation, price transparency, logistics coordination, and trade financing (RIFF and a $5M Matching Fund) to reduce medicine procurement costs by over 35% for governments, NGOs, and mission-driven private procurers in LMICs.
Is Axmed a public or private company?
Axmed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Axmed founded?
Axmed was founded in 2024. It employs 11 to 50 people.
Where is Axmed based?
Axmed is headquartered in Basel, Switzerland, in the Europe region.
How does Axmed make money?
Two revenue lines are on record. Marketplace Transaction Fees are the primary driver. The others are logistics and Financing Services.
Who are Axmed's main competitors?
Direct peers on record are mPharma, Field Intelligence, DrugStoc, RxAll, Shelf Life, Sproxil and PharmaSecure. Zipline is listed as an emerging player.
Does Axmed have an API?
No public API is recorded for Axmed.
What industry is Axmed in?
Axmed's product category is Healthcare Procurement Marketplace. Its primary akta.pro industry code is BPAMAGAD, B2B Marketplaces & Wholesale Platforms, with a secondary code of HLAIAKAA, Pricing & Contracting Strategy. Its NAICS code is 424210 and its SIC code is 5122.